GlassScriptPhysician profile
Farrukh Ashraf
NPI 1972730885
$4,496.13
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,261 · 2020: $199 · 2021: $87.91 · 2022: $460 · 2023: $1,279 · 2024: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,467 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,466.96 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $1,979.78 | 2019-2023 | Adcetris, Tukysa |
| Astrazeneca Pharmaceuticals LP | $332.38 | 2019-2024 | Enhertu, Calquence, Tagrisso |
| Takeda Pharmaceuticals U.S.A., INC. | $286.25 | 2019-2024 | Ninlaro |
| Janssen Biotech, INC. | $234.42 | 2019-2023 | Darzalex |
| Regeneron Healthcare Solutions, INC. | $173.21 | 2022-2024 | Libtayo |
| Incyte Corporation | $141.94 | 2019-2023 | Jakafi |
| Daiichi Sankyo INC. | $136.71 | 2019-2024 | Enhertu, Injectafer |
| Novartis Pharmaceuticals Corporation | $126.76 | 2019-2023 | |
| Amgen INC. | $102.74 | 2019-2023 | Lumakras, Nplate, Xgeva |
| Bayer Healthcare Pharmaceuticals INC. | $102.16 | 2023 | |
| Genentech USA, INC. | $93.76 | 2019-2023 | Tecentriq, Alecensa, Gavreto |
| Mirati Therapeutics, INC. | $89.29 | 2023 | Krazati |
| Pfizer INC. | $85.26 | 2019-2023 | |
| Array Biopharma INC | $53.25 | 2022-2023 | Braftovi, Mektovi, Xalkori |
| Merck Sharp & Dohme LLC | $49.77 | 2023-2024 | Lynparza, Keytruda |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $48.36 | 2021-2024 | |
| Agios Pharmaceuticals, INC. | $48.09 | 2019 | |
| Alexion Pharmaceuticals, INC. | $48.09 | 2023 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $46.38 | 2020-2023 | Opdivo |
| Celgene Corporation | $37.02 | 2019-2023 | Pomalyst |
| Puma Biotechnology, INC. | $36.57 | 2023 | |
| Genzyme Corporation | $33.14 | 2024 | |
| Exelixis INC. | $31.19 | 2023 | Cabometyx |
| Jazz Pharmaceuticals INC. | $27.33 | 2024 | |
| Abbvie INC. | $26.80 | 2023 | Venclexta |
| Rigel Pharmaceuticals, INC. | $21.34 | 2023 | Rezlidhia, Tavalisse |
| Lilly USA, LLC | $18.81 | 2023 | Jaypirca, Retevmo, Verzenio |
| Morphosys, US INC. | $18.81 | 2023 | Monjuvi |
| Amag Pharmaceuticals, INC. | $17.96 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $17.70 | 2022 | |
| Foundation Medicine, INC. | $17.06 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $13.80 | 2023 | Imbruvica |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farrukh Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.